Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Stock Information for Oncolytics Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncolytics Biotech Inc.

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
After Major Oncology Conference, All Eyes Turn to Industry Innovation
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.